Clinical Trial Update: nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation [Phase 3]

View source ↗

Summary

Phase 3 trial of the nMARQ Pulmonary Vein Isolation System for paroxysmal atrial fibrillation was terminated, with results posted in December 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• nMARQ Pulmonary Vein Isolation System

Snippet

Sponsor: Biosense Webster, Inc. | Conditions: Atrial Fibrillation | Phase 3 | Status: TERMINATED | Results posted: 2018-12-12